145 related articles for article (PubMed ID: 23334061)
21. Dose Escalation Study of Concurrent Chemoradiotherapy With the Use of Involved-field Conformal Radiotherapy and Accelerated Hyperfractionation in Combination With Cisplatin and Vinorelbine Chemotherapy for Stage III Non-small Cell Lung Cancer: The Final Report.
Yoshimura N; Tada T; Matsumoto Y; Sawa K; Yoshimoto N; Suzumura T; Tanaka H; Mitsuoka S; Kimura T; Tamiya T; Hirashima T; Kawaguchi T; Kudoh S; Hosono M; Hirata K
Am J Clin Oncol; 2018 Oct; 41(10):967-971. PubMed ID: 29045265
[TBL] [Abstract][Full Text] [Related]
22. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer.
De Jaeger K; Seppenwoolde Y; Kampinga HH; Boersma LJ; Belderbos JS; Lebesque JV
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1378-87. PubMed ID: 15050313
[TBL] [Abstract][Full Text] [Related]
23. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database.
Werner-Wasik M; Paulus R; Curran WJ; Byhardt R
Clin Lung Cancer; 2011 Jul; 12(4):245-51. PubMed ID: 21726824
[TBL] [Abstract][Full Text] [Related]
24. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
[TBL] [Abstract][Full Text] [Related]
25. Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol.
Ninomiya K; Ichihara E; Hotta K; Sone N; Murakami T; Harada D; Oze I; Kubo T; Tanaka H; Kuyama S; Kishino D; Bessho A; Harita S; Katsui K; Tanimoto M; Kiura K
Clin Lung Cancer; 2017 Mar; 18(2):245-249. PubMed ID: 27847247
[TBL] [Abstract][Full Text] [Related]
26. Predicting Radiation Esophagitis Using 18F-FDG PET During Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
Mehmood Q; Sun A; Becker N; Higgins J; Marshall A; Le LW; Vines DC; McCloskey P; Ford V; Clarke K; Yap M; Bezjak A; Bissonnette JP
J Thorac Oncol; 2016 Feb; 11(2):213-21. PubMed ID: 26718880
[TBL] [Abstract][Full Text] [Related]
27. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
[TBL] [Abstract][Full Text] [Related]
28. A model combining age, equivalent uniform dose and IL-8 may predict radiation esophagitis in patients with non-small cell lung cancer.
Wang S; Campbell J; Stenmark MH; Stanton P; Zhao J; Matuszak MM; Ten Haken RK; Kong FM
Radiother Oncol; 2018 Mar; 126(3):506-510. PubMed ID: 29496281
[TBL] [Abstract][Full Text] [Related]
29. Influence of ACE I/D Polymorphism on Circulating Levels of Plasminogen Activator Inhibitor 1, D-Dimer, Ultrasensitive C-Reactive Protein and Transforming Growth Factor β1 in Patients Undergoing Hemodialysis.
de Carvalho SS; Simões e Silva AC; Sabino Ade P; Evangelista FC; Gomes KB; Dusse LM; Rios DR
PLoS One; 2016; 11(3):e0150613. PubMed ID: 27022914
[TBL] [Abstract][Full Text] [Related]
30. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma.
Kong F; Jirtle RL; Huang DH; Clough RW; Anscher MS
Cancer; 1999 Nov; 86(9):1712-9. PubMed ID: 10547543
[TBL] [Abstract][Full Text] [Related]
31. Association of oesophageal radiation dose volume metrics, neutropenia and acute radiation oesophagitis in patients receiving chemoradiotherapy for non-small cell lung cancer.
Everitt S; Duffy M; Bressel M; McInnes B; Russell C; Sevitt T; Ball D
Radiat Oncol; 2016 Feb; 11():20. PubMed ID: 26864559
[TBL] [Abstract][Full Text] [Related]
32. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Ready N; Jänne PA; Bogart J; Dipetrillo T; Garst J; Graziano S; Gu L; Wang X; Green MR; Vokes EE;
J Thorac Oncol; 2010 Sep; 5(9):1382-90. PubMed ID: 20686428
[TBL] [Abstract][Full Text] [Related]
33. Association of Target Volume Margins With Locoregional Control and Acute Toxicities for Non-small cell lung cancer Treated With Concurrent Chemoradiation Therapy.
Yegya-Raman N; Reyhan M; Kim S; Deek MP; Yue N; Zou W; Malhotra J; Aisner J; Jabbour SK
Pract Radiat Oncol; 2019 Jan; 9(1):e74-e82. PubMed ID: 30144583
[TBL] [Abstract][Full Text] [Related]
34. A polymorphism within the promoter of the TGFβ1 gene is associated with radiation sensitivity using an objective radiologic endpoint.
Kelsey CR; Jackson L; Langdon S; Owzar K; Hubbs J; Vujaskovic Z; Das S; Marks LB
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e247-55. PubMed ID: 21605940
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy and toxicity of induction chemotherapy with concurrent stereotactic body radiotherapy and stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma.
Sun Y; Duan Q; Chen X; Chen W; Jin X; Wu R
Clin Transl Oncol; 2017 Dec; 19(12):1498-1506. PubMed ID: 28589432
[TBL] [Abstract][Full Text] [Related]
36. S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial.
Yao L; Xu S; Xu J; Yang C; Wang J; Sun D
Radiat Oncol; 2015 Jan; 10():10. PubMed ID: 25572571
[TBL] [Abstract][Full Text] [Related]
37. Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy.
Guan X; Yin M; Wei Q; Zhao H; Liu Z; Wang LE; Yuan X; O'Reilly MS; Komaki R; Liao Z
BMC Cancer; 2010 Aug; 10():431. PubMed ID: 20712888
[TBL] [Abstract][Full Text] [Related]
38. A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305.
Tada T; Chiba Y; Tsujino K; Fukuda H; Nishimura Y; Kokubo M; Negoro S; Kudoh S; Fukuoka M; Nakagawa K; Nakanishi Y
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):327-31. PubMed ID: 22079726
[TBL] [Abstract][Full Text] [Related]
39. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
Antonadou D
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):50-8. PubMed ID: 11917285
[TBL] [Abstract][Full Text] [Related]
40. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
